[go: up one dir, main page]

NO20081628L - Benzodiazepiner som HCV-inhibitorer - Google Patents

Benzodiazepiner som HCV-inhibitorer

Info

Publication number
NO20081628L
NO20081628L NO20081628A NO20081628A NO20081628L NO 20081628 L NO20081628 L NO 20081628L NO 20081628 A NO20081628 A NO 20081628A NO 20081628 A NO20081628 A NO 20081628A NO 20081628 L NO20081628 L NO 20081628L
Authority
NO
Norway
Prior art keywords
benzodiazepines
relates
present
hcv
compounds
Prior art date
Application number
NO20081628A
Other languages
English (en)
Inventor
Frederic Marc Maurice Doublet
Jean-Francois Bonfanti
Origene Nyanguile
Pierre Jean-Marie Be Raboisson
Anne-Sophie Helene Ma Rebstock
Carlo Willy Maurice Boutton
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of NO20081628L publication Critical patent/NO20081628L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelsen angår anvendelse av benzodiazepiner som inhibitorer av HCV-replikasjon så vel som deres anvendelse i farmasøytiske sammensetninger med siktemål å behandle eller bekjempe HCV-infeksjoner. I tillegg angår foreliggende oppfinnelse benzodiazepinforbindelser i seg selv og deres anvendelse som medisiner. Foreliggende oppfinnelse angår også fremgangsmåte for fremstilling av slike forbindelser, farmasøytiske sammensetninger som innebefatter dem og kombinasjoner av nevnte forbindelser med andre anti-HCV-midler.
NO20081628A 2005-09-02 2008-04-02 Benzodiazepiner som HCV-inhibitorer NO20081628L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05108058 2005-09-02
EP05110606 2005-11-10
PCT/EP2006/065938 WO2007026024A2 (en) 2005-09-02 2006-09-01 Benzodiazepines as hcv inhibitors

Publications (1)

Publication Number Publication Date
NO20081628L true NO20081628L (no) 2008-05-29

Family

ID=37719242

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081628A NO20081628L (no) 2005-09-02 2008-04-02 Benzodiazepiner som HCV-inhibitorer

Country Status (14)

Country Link
US (1) US20090221559A1 (no)
EP (1) EP1937272A2 (no)
JP (1) JP2009507004A (no)
KR (1) KR20080040032A (no)
AR (1) AR056193A1 (no)
AU (1) AU2006286441A1 (no)
BR (1) BRPI0615922A2 (no)
CA (1) CA2620777A1 (no)
IL (1) IL189626A0 (no)
MX (1) MX2008003032A (no)
NO (1) NO20081628L (no)
RU (1) RU2008112661A (no)
TW (1) TW200800225A (no)
WO (1) WO2007026024A2 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008099019A1 (en) * 2007-02-16 2008-08-21 Tibotec Pharmaceuticals Ltd. 6-hydroxy-dibenzodiazepinones useful as hepatitis c virus inhibitors
WO2008099021A1 (en) * 2007-02-16 2008-08-21 Tibotec Pharmaceuticals Ltd. Dibenzodiazepinones useful as hepatitis c virus inhibitors
PL2238142T3 (pl) 2007-12-24 2012-11-30 Janssen R&D Ireland Makrocykliczne indole jako inhibitory wirusa zapalenia wątroby typu C
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
WO2011029054A1 (en) 2009-09-04 2011-03-10 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
CA2801517C (en) 2010-06-24 2017-12-12 Janssen R&D Ireland Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7h-indolo-[2,1-.alpha.]-[2]-benzazepine-10-carboxylic acid
WO2013068592A1 (en) * 2011-11-10 2013-05-16 Fondation Jerome Lejeune Inhibitors of cystathionine beta synthase to reduce the neurotoxic overproduction of endogenous hydrogen sulfide
CN104271132B (zh) 2011-12-21 2018-01-12 科罗拉多大学董事会法人团体 靶向Ral GTP酶的抗癌化合物及使用其的方法
CN103601721B (zh) * 2013-10-23 2016-04-27 江苏科技大学 3-呋喃基二苯并二氮卓-1-酮类系列衍生物及其制备方法和应用
EP3166609B1 (en) 2014-07-10 2020-03-11 The Regents of The University of Colorado, A Body Corporate 6-amino-1,3-dimethyl-4-(4-(trifluoromethyl)phenyl)-1,4-dihydropyrano [2,3-c]pyrazole-5-carbonitrile and related compounds as ral gtpase inhibitors for treating cancer metastasis
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
US10588907B2 (en) 2015-06-04 2020-03-17 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
BR112018068703B1 (pt) 2016-03-16 2024-02-06 Kura Oncology, Inc. Inibidores substituídos de menin-mll e métodos de uso
KR102419524B1 (ko) 2016-03-16 2022-07-08 쿠라 온콜로지, 인크. 메닌-mll의 가교된 이환식 억제제 및 사용 방법
CN117298275A (zh) 2017-03-24 2023-12-29 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
EP2062583B1 (en) * 1999-04-30 2012-12-26 The Regents of the University of Michigan Therapeutic applications of pro-apoptotic benzodiazepines
WO2004001058A2 (en) * 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
US20050123906A1 (en) * 2003-11-06 2005-06-09 Rana Tariq M. Protein modulation

Also Published As

Publication number Publication date
IL189626A0 (en) 2008-08-07
EP1937272A2 (en) 2008-07-02
WO2007026024A2 (en) 2007-03-08
AR056193A1 (es) 2007-09-26
MX2008003032A (es) 2008-03-24
BRPI0615922A2 (pt) 2011-05-31
KR20080040032A (ko) 2008-05-07
US20090221559A1 (en) 2009-09-03
WO2007026024A3 (en) 2007-04-26
AU2006286441A1 (en) 2007-03-08
JP2009507004A (ja) 2009-02-19
CA2620777A1 (en) 2007-03-08
RU2008112661A (ru) 2009-10-10
TW200800225A (en) 2008-01-01

Similar Documents

Publication Publication Date Title
NO20081628L (no) Benzodiazepiner som HCV-inhibitorer
NO20072235L (no) HCV-hemmende bicykliske pyrimidiner
NO20080540L (no) HCV-inhibitorer
MX2007014082A (es) Pirido[2,3-d]pirimidinas utiles como inhibidores del virus de la hepatitis c (hcv), y metodos para la preparacion de las mismas.
UY30759A1 (es) Compuestos quimicos
NO20091258L (no) Entantiomerisk rene fosfoindoler as HIV inhibitorer
NO20064584L (no) Tetrahydropyridoindolderivater
NO20090628L (no) Pyridizinon derivativater
NO20084256L (no) DPP IV inhibitorformuleringer
NO20085176L (no) Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter
NO20073105L (no) Pyridazinonforbindelser
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
MX2009011533A (es) Productos quimicos, composiciones y metodos para tratamiento y prevencion de infecciones de virus orthopox y enfermedades asociadas.
NO20082269L (no) Nye piperaziner som antimalariamidler
CL2008000959A1 (es) Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c.
NO20060978L (no) Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering
WO2007084424A3 (en) Treatment of substance abuse
BRPI0514736A (pt) inibidores do receptor sigma
NO20084352L (no) Dimerer av artemisininderivater, fremstilling derav og terapeutisk anvendelse derav
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
CL2008003231A1 (es) Compuestos derivados de 1,3-dihidro-5-isobenzofurancarbonitrilo sustituido, inhibidores selectivos de la recaptacion de serotonina; composicion farmaceutica; procedimiento de preparacion; utiles en el tratamiento y/o prevencion de la eyaculacion prematura.
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
WO2004099165A3 (en) Heterocyclic compounds and hydro isomers thereof
NO20074528L (no) Substituerte pyrroler, sammensetninger, fremgangsmate for fremstilling og anvendelse av samme
IL191670A0 (en) Compounds for the inhibition of apoptosis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application